Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Berlin

Showing results (181-190 of 221) with videos related to

Pageof 23
Sort By:
JAMA Oncology|January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A ReviewRachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
European Urology|January 9, 2021
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedMatthew P Deek, Kim Van der Eecken, Ryan Phillips, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 TrialDaniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|December 19, 2021
An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate CancerSoumyajit Roy, Nicholas G Zaorsky, Hilary P Bagshaw, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
European Urology Oncology|April 3, 2024
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate CancerMatthew P Deek, Philip Sutera, Yuezhou Jing, et al.
Physics in Medicine and Biology|June 6, 2025
Roadmap: medical physics technologies in brachytherapyWilliam Y Song, Michael Roumeliotis, Junghoon Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancerJarey H Wang, Matthew P Deek, Adrianna A Mendes, et al.
Pageof 23

Showing results (181-190 of 221) with videos related to

Sort By:
Pageof 23
JAMA Oncology|January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A ReviewRachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
European Urology|January 9, 2021
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedMatthew P Deek, Kim Van der Eecken, Ryan Phillips, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 TrialDaniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
International Journal of Radiation Oncology, Biology, Physics|December 19, 2021
An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate CancerSoumyajit Roy, Nicholas G Zaorsky, Hilary P Bagshaw, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
European Urology Oncology|April 3, 2024
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate CancerMatthew P Deek, Philip Sutera, Yuezhou Jing, et al.
Physics in Medicine and Biology|June 6, 2025
Roadmap: medical physics technologies in brachytherapyWilliam Y Song, Michael Roumeliotis, Junghoon Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancerJarey H Wang, Matthew P Deek, Adrianna A Mendes, et al.
Pageof 23